“…However, in macrophages [ 28 ], the transcripts of at least 16 different subtypes (TAS2Rs 3, 4, 5, 7, 8, 9, 10, 14, 19, 20, 31, 38, 39, 43, 45 and 46) have been detected. Both in resident and monocyte-derived macrophages, bitter agonists inhibit cytokine release [ 58 ] and cell migration [ 85 , 86 ] and stimulate reactive species release [ 61 ]. In mast cells, TAS2R3, 4, 10, 14 and 46 are well-expressed and are hypothesized to exert an inhibitory function on leukocytes, particularly by counteracting the release of histamine in IgE-activated cells [ 87 , 88 ].…”